Effects of 4-(2-alkylthio-1-benzyl-5-imidazolyl)-dihydropyridines on the isolated rat colon and right atrium contractility

Iranian Journal of Basic Medical Sciences

Volumn 11, Issue 3, 2008, Pages 159-165

  Hadizadeh, Farzin ^a   Fatehi, Mohammad ^b   Fatehi Hassanabad, Zahra ^b   Zandieh, Mojgan ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Atlantic Centre for Comparative Biomedical Research   (Canada)

Author keywords

Colon; Dihydropyridines; Heart atria; Myocardial contraction; Rat

Indexed keywords

4 (2 ALKYLTHIO 1 BENZYL 5 IMIDAZOLYL) DIHYDROPYRIDINE; NIFEDIPINE DERIVATIVE; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLONIC MUSCLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RESPONSE; HEART ATRIUM CONTRACTILITY; INOTROPISM; MALE; MUSCLE CONTRACTION; NONHUMAN; RAT;

EID: 80052536723     PISSN: 20083866     EISSN: 20083874     Source Type: Journal    
DOI: 10.22038/IJBMS.2008.5226     Document Type: Article

References (26)

1. Fleckenstien A. Pecific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1977; 17:149.
2. Ramesh M, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of alkyl t-butyl esters of nifedipine analogues containing pyridinyl substituents. Drug Des Deliv 1987; 2:79-89.
3. Akula MR, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of alkyl cycloalkyl esters of nifedipine containing pyridinyl substituents. Drug Des Deliv 1989; 5:117-123.
4. Ramesh M, Matowe WC, Knaus EE, Wolowyk MW. Synthesis and calcium channel antagonist activity of dialkyl 1, 4-dihydro-2, 6-dimethyl-4-[3-(1-methoxy-carbonyl-4-substituted-1,4- dihydro-pyridyl)]-3,5-pyridinedicarboxylates. Drug Des Discov 1992; 8:313-323.
5. Akula MR, Matowe WC, Wolowyk MW, Knaus EE. Synthesis and calcium channel antagonist activity of 3-arylmethyl 5-isopropyl 1,4-dihydro-2,6-dimethyl-4-(pyridyl)-3,5-pyridinedicarboxylates. Pharm Res 1990; 7:919-922.
6. Vo D, Matowe WC, Ramesh M, Iqbal N, Wolowyk MW, Howlett SE, et al. Syntheses, calcium channel agonist-antagonist modulation activities, and voltage-clamp studies of isopropyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridinylpyridine-5-carboxylate racemates and enantiomers. J Med Chem 1995; 38:2851-2859.
7. Mahmoudian M, Mirkhani H, Nehardani Z, Ghiaee S. Synthesis and biological activity of two new calcium-channel blockers, mebudipine and dibudipine. J Pharm Pharmacol 1997; 49:1229-1233.
8. Shafiee A, Dehpour AR, Hadizadeh F, Azimi M. Syntheses and calcium channel antagonist activity of nifedipine analogue with methylsulfonylimidazolyl substituent. Pharma Acta Helv 1998; 73:75-79.
9. Triggle DG. Biochemical and pharmacological differences among calcium channel antagonists: clinical implications. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia, PA: Hanley & Belfus, Inc.; 1992:1-27.
10. Iqbal N, Vo D, McEwen CA, Wolowyk MW, Knaus EE. Enantioselective syntheses and calcium channel modulating effects of (+)- and (-)-3-isopropyl 5-(4-methylphenethyl)1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)-3,5-pyridinedicarboxylates. Chirality 1994; 6:515-520.
11. Baraldi P, Garuti L, Leonin A. Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridinedicarboxylates. Drug Des Discov 1993; 10:319.
12. Shafiee A, Miri R, Dehpour AR. Synthesis and calcium cannel antagonist-activity of nifedipine analogues containing nitroimidazolyl substituents. Pharm Sci 1996; 2:541.
13. Amini A, Dehpour AR, Shafiee A. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloromidazolyl substituents. Arzneim Forsch / Drug Res 2002; 52:21.
14. Shafiee A, Rastkary N, Jorjani M. Synthesis and calcium channel antagonist-activity of 1,4- dihyropyridine derivatives containing 4-nitro imidazolyl substituents. Arzneim Forsch / Drug Res 2002; 52:537.
15. Pourmorad F, Hadizadeh F, Shafiee A. Synthesis and calcium channel antagonist activity of 4- imidazolyl-1,4-dihydropyridines. Pharm Sci 1997; 3:165.
16. Zarghi A, Derakhshandeh K, Roshanzamir F. Synthesis and calcium channel antagonist activity of new 1, 4-dihyropyridines containing nitrobenzyl imidazolyl substituent. Boll Chim Farm 2002; 141:15.
17. Hadizadeh F, Shafiee A, Kazemi R, Mohammadi M. Synthesis of 4-(1-phenylmethyl-5-imidazolyl)-1,4-dihydropyridines as calcium channel antagonists. Indian J Chem Sec B 2002; 41:2679.
18. Miri R, Javidnia K, Sarkarzadeh H, Hemmateenejad B. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg Med Chem 2006; 14:4842-4849.
19. Nasa Y, Ichihara K, Yshida R, Abiko Y. Positive inotropic and negative chronotropic effects of (-)-cis-diltiazem in rat isolated atria. Br J Pharmacol 1992; 105: 696-702.
20. Gurkan A, Birgul Y, Ziya K. Direct cardiac effects in isolated perfused rat hearts of fentanyl and remifentanil. Ann Card Anaesth 2005; 8: 140-144.
21. Christensen J, Stiles MJ, Rick GA, Sutherland J. Comparative anatomy of the myenteric plexus of the distal colon in eight mammals. Gastroenterology 1984; 86:706-713.
22. Ek BA, Bjellin LA, Lundgren BT. Beta-adrenergic control of contraction in the rat colon. I. Evidence for functional separation of the beta 1- and beta 2-adrenoceptor-mediated inhibition of colon activity. Gastroenterology 1986; 90:400-407.
23. Serio R, Mule F, Postorino A. Nonadrenergic, noncholinergic inhibitory junction potentials in rat proximal colon: role of nitric oxide. Can J Physiol Pharmacol 1995; 73:79-84.
24. Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol 1998; 21:II3-7.
25. Hockerman GH, Peterson BZ, Johnson BD, Catterall WA. Molecular determinants of drug binding and action on L-type calcium channels. Ann Rev Pharmacol Toxicol 1997; 37:361-396.
26. Zhang Z, Xu Y, Song H, Rodriguez J, Tuteja D, and Namkung Y, et al. Functional roles of Ca (v) 1.3 (alpha (1D) calcium channel in sinoatrial nodes: insight gained using gene-targeted null mutant mice. Circ Res 2002; 90:981-987.